Related Experiment Video
Updated: Jan 8, 2026
06:06
Tissue Collection and RNA Extraction from the Human Osteoarthritic Knee Joint
Published on: July 22, 2021
6.7K
Prevalence of Arthritis-Attributable Activity Limitations - United States, 2023
Ellen W Stowe1, Daniel K White2, Michael A Boring3
1Centers for Disease Control and Prevention, Atlanta, Georgia.
Arthritis Care & Research
|December 16, 2025
Summary
Nearly half of US adults with arthritis experience activity limitations. Despite a slight decline, the Healthy People 2030 goal to reduce arthritis-attributable activity limitations (AAAL) was not met between 2019 and 2023.
Area of Science:
- Public Health
- Epidemiology
- Gerontology
Background:
- Arthritis affects millions of US adults, often leading to activity limitations.
- Arthritis-attributable activity limitations (AAAL) are a key indicator for public health initiatives.
- The Healthy People 2030 framework aims to reduce AAAL prevalence.
Purpose of the Study:
- To estimate the 2023 prevalence of AAAL among US adults with arthritis.
- To analyze AAAL prevalence by sociodemographic and health characteristics.
- To assess progress towards the Healthy People 2030 goal for AAAL reduction.
Main Methods:
- Utilized cross-sectional data from the 2019 and 2023 National Health Interview Survey.
- Estimated unadjusted and age-standardized AAAL prevalences for US adults with diagnosed arthritis.
- Employed t-tests to assess differences in AAAL prevalence across various characteristics and survey years.
Main Results:
- In 2023, the age-adjusted prevalence of AAAL was 47.8% (24.8 million adults).
- Significant variations in AAAL prevalence were observed across sociodemographic and health groups.
- A non-statistically significant decline in AAAL prevalence occurred from 49.2% in 2019 to 47.8% in 2023.
Conclusions:
- Approximately half of US adults with arthritis report activity limitations.
- The Healthy People 2030 target prevalence of 46.8% for AAAL was not achieved.
- Implementing evidence-based interventions is crucial for meeting the Healthy People 2030 AAAL reduction goal.
Related Concept Videos
01:11Genome-wide Association Studies-GWAS
15.2K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
15.2K
01:08Prevalence and Incidence
1.5K
In statistical epidemiology and health sciences, two essential metrics—prevalence and incidence—are fundamental for understanding disease dynamics within a population. These measures enable public health officials, epidemiologists, and researchers to assess the burden of diseases, allocate resources effectively, and design impactful public health policies and interventions.
Prevalence indicates the proportion of individuals in a population who have a specific disease or health...
Prevalence indicates the proportion of individuals in a population who have a specific disease or health...
1.5K
01:20The JAK-STAT Signaling Pathway
11.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
11.8K
01:26Atherosclerosis III: Management
293
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
293
01:21Rheumatic Heart Disease III: Medical Management
264
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
264
01:27Peripheral Artery Disease III: Interprofessional Care
221
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
221